Clinical Study
Relation of Biomarkers of Inflammation and Oxidative Stress with Hypertension Occurrence in Lone Atrial Fibrillation
Table 2
Development of vascular disease in lone AF patients and healthy controls.
| | | AF patients
| SR controls
| value |
| | VD development | 14 (28.0) | 5 (11.4) | 0.045 | | Time to VD development (months) | 28 (9–42) | 34 (17.5–39.5) | 0.391 | | Age at VD development | 56.8 ± 8.3 | 61.8 ± 3.7 | 0.031 | | Medical therapy prior to VD development | | | | | Beta-blockers | 20 (40.0) | — | — | | Non-dihydropyridine Ca2+ channel antagonists | 2 (4.0) | — | — | | Digoxin | 0 (0.0) | — | — | | Propafenone | 14 (28.0) | — | — | | Sotalol | 1 (2.0) | — | — | | Amiodarone | 20 (40.0) | — | — | | Vitamin K antagonists | 6 (12.0) | — | — | | Aspirin | 1 (2.0) | — | — | | Statins | 3 (6.0) | 4 (9.1) | 0.414 |
|
|
AF: atrial fibrillation; SR: sinus rhythm; VD: vascular disease.
|
